Nuvectis Pharma stock analysis
Want to see NVCT full AI Analyst Report?
Nuvectis Pharma (NVCT) Stock Price & Analysis
NVCT Stock Chart & Stats
- Day’s Range
- $18.65 - $20.37
- 52-Week Range
- $5.77 - $29.28
- Previous Close
- $19.20
- Volume
- N/A
- Average Volume (3M)
- 200.75K
- Market Cap
- $697.75M
- Enterprise Value
- $481.63M
- Total Cash (Recent Filing)
- $140.71M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 0.13
- Next Earnings
- Mar 09, 2027 (Est.)
- EPS Estimate
- -0.37
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
Zero reported debt reduces solvency pressure and preserves flexibility while the company advances clinical programs. The move from negative equity in 2021 to substantial positive equity and assets also provides a stronger financial base for development spending over the next several quarters.
Extended Cash Runway
A stated cash runway into the second half of 2029 gives Nuvectis time to pursue regulatory filings, trials, and pipeline development without relying immediately on operating revenue. This supports continuity of execution across several planned clinical and regulatory milestones.
Validated Late-stage Pipeline
China approval for NXP-100 and encouraging NXP-200 response data materially strengthen the pipeline beyond an entirely early-stage profile. These assets offer multiple potential development and commercialization paths across PNH, kidney disease, glioma, and other solid tumors.
Bears Say
Pre-revenue Business Model
The absence of reported revenue means Nuvectis has not yet demonstrated commercial traction or operating leverage. Until a candidate reaches the market and generates sales, the company must fund development through its balance sheet and external capital rather than internally generated business cash.
Widening Losses And Cash Burn
Rising losses and sustained negative operating and free cash flow increase the resources required to advance the pipeline. Even with current liquidity, continued spending without revenue raises the likelihood that future development may require additional financing or tighter capital allocation.
Unresolved U.S. Regulatory Path
Uncertainty over the U.S. development requirements could extend timelines, increase clinical costs, and delay access to a major market for NXP-100. The need for one or more additional studies would also consume capital and create execution risk despite constructive FDA discussions.
Nuvectis Pharma News
Joseph Pantginis Lifts Nuvectis Pharma Price Target to $39 on Strong NXP200 Glioma Data, Maintains Buy Rating
Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma, boosting the price target to $39.00. Joseph Pantginis has given his Buy rating due to a combination
Nuvectis: Buy Rating Reaffirmed as NXP Pipeline Progress and Regulatory Momentum Support Unchanged $39 Price Target
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target remains the same with $39.00. Joseph Pantginis has given his Buy rating
Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Pete Stavropoulos initiated coverage of Nuvectis Pharma (NVCT) with an Overweight rating. Nuvectis’ NXP100 offers a potentially differentiated, once-daily oral Factor B inhibitor with Phase 3 validation
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
What is Nuvectis Pharma’s market cap?
When is Nuvectis Pharma’s upcoming earnings report date?
How were Nuvectis Pharma’s earnings last quarter?
Is Nuvectis Pharma overvalued?
Does Nuvectis Pharma pay dividends?
What is Nuvectis Pharma’s EPS estimate?
How many shares outstanding does Nuvectis Pharma have?
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Nuvectis Pharma?
What is the TipRanks Smart Score and how is it calculated?
Nuvectis Pharma Stock Smart Score
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ron Bentsur
- Employees
- 13
- Website
- www.nuvectis.com
- Address
- 1 Bridge Plaza, Fort Lee, NJ, 07024, US
Nuvectis Pharma (NVCT) Earnings & Revenues
NVCT Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by the transformation into a late-stage development company, the China approval of NXP-100, encouraging NXP-100 and NXP-200 clinical data, substantial financing, and a cash runway into the second half of 2029. The primary challenges were the reported quarterly net loss, the unresolved FDA requirements for U.S. PNH development, and the need for additional NXP-200 solid tumor data, but these issues were outweighed by the number and significance of the stated achievements and upcoming catalysts.
View all NVCT earnings summariesNVCT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 11 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 3 | 0 | 9 |













